Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2007

View Archived Issues

Experimental therapies in uveitis presented at the ARVO meeting

Safety and immunogenicity of novel virus-like particle-based HIV vaccine

L-Ergothioneine shown to increase sperm viability

New TrkA receptor agonist potentiates betaxolol antiglaucoma activity

Trexima migraine relief consistent within patients

Novel antiinfective agents disclosed in recent patent literature

Recent patent reports novel therapeutic agents for HIV infection

New alpha-fetoprotein-derived peptides as potential therapies for tamoxifen-resistant breast cancer

Novel treatment options for obesity and other metabolic disorders reported in recent patents

Merck KGaA's generic business to be acquired by Mylan Laboratories

NICE recommends Actilyse for treatment of acute ischemic stroke

Oral Belerofon to enter clinical trials in U.S.

Expanded indication for Questcor's Acthar Gel deemed not approvable by FDA

New Sular formulation demonstrates bioequivalence

Taxus OLYMPIA registry makes stride in patient enrollment

Dyax commences phase II with DX-88

Momenta Pharmaceuticals begins phase I trial of subcutaneous next-generation anticoagulant

Vical reports memory T-cell immune response for DNA vaccine

FDA gives go ahead for melanoma vaccine using TriGrid delivery system

Additional statistically significant phase III data reported for BEMA-fentanyl

Pro-Pharmaceuticals provides clinical update on Davanat

VGX Pharmaceuticals and Baylor College of Medicine enter GHRH license agreement

New FDA approval sought for Aloxi: prevention of PONV

CV Therapeutics seeks FDA approval of regadenoson for use in MPI

FDA approves liquid fibrin sealant for use in vascular surgery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...